Cancers (Oct 2020)
Progression-Free Survival and Overall Survival in Patients with Advanced HER2-Positive Breast Cancer Treated with Trastuzumab Emtansine (T-DM1) after Previous Treatment with Pertuzumab
- Laura L. Michel,
- Andreas D. Hartkopf,
- Peter A. Fasching,
- Hans-Christian Kolberg,
- Peyman Hadji,
- Hans Tesch,
- Lothar Häberle,
- Johannes Ettl,
- Diana Lüftner,
- Markus Wallwiener,
- Volkmar Müller,
- Matthias W. Beckmann,
- Erik Belleville,
- Bernhard Volz,
- Hanna Huebner,
- Pauline Wimberger,
- Carsten Hielscher,
- Christoph Mundhenke,
- Christian Kurbacher,
- Rachel Wuerstlein,
- Michael Untch,
- Friedrich Overkamp,
- Jens Huober,
- Wolfgang Janni,
- Florin-Andrei Taran,
- Michael P. Lux,
- Diethelm Wallwiener,
- Sara Y. Brucker,
- Andreas Schneeweiss,
- Tanja N. Fehm
Affiliations
- Laura L. Michel
- Department of Gynecology and Obstetrics, Heidelberg University Hospital, 69120 Heidelberg, Germany
- Andreas D. Hartkopf
- Department of Obstetrics and Gynecology, University of Tübingen, 72076 Tübingen, Germany
- Peter A. Fasching
- Department of Gynecology and Obstetrics, Erlangen University Hospital, Comprehensive Cancer Center Erlangen-EMN, Friedrich Alexander University of Erlangen-Nuremberg, 91054 Erlangen, Germany
- Hans-Christian Kolberg
- Department of Gynecology and Obstetrics, Marienhospital Bottrop, 46236 Bottrop, Germany
- Peyman Hadji
- Frankfurt Center for Bone Health, 60313 Frankfurt am Main, Germany
- Hans Tesch
- Oncology Practice, Bethanien Hospital, 60389 Frankfurt am Main, Germany
- Lothar Häberle
- Department of Gynecology and Obstetrics, Erlangen University Hospital, Comprehensive Cancer Center Erlangen-EMN, Friedrich Alexander University of Erlangen-Nuremberg, 91054 Erlangen, Germany
- Johannes Ettl
- Department of Obstetrics and Gynecology, Klinikum rechts der Isar, Technical University of Munich, 81675 Munich, Germany
- Diana Lüftner
- Department of Hematology, Oncology and Tumor Immunology, Charité University Hospital, Campus Benjamin Franklin, 12203 Berlin, Germany
- Markus Wallwiener
- Department of Gynecology and Obstetrics, Heidelberg University Hospital, 69120 Heidelberg, Germany
- Volkmar Müller
- Department of Gynecology, Hamburg-Eppendorf University Medical Center, 20246 Hamburg, Germany
- Matthias W. Beckmann
- Department of Gynecology and Obstetrics, Erlangen University Hospital, Comprehensive Cancer Center Erlangen-EMN, Friedrich Alexander University of Erlangen-Nuremberg, 91054 Erlangen, Germany
- Erik Belleville
- ClinSol GmbH & Co KG, 97074 Würzburg, Germany
- Bernhard Volz
- Ansbach University of Applied Sciences, 91522 Ansbach, Germany
- Hanna Huebner
- Department of Gynecology and Obstetrics, Erlangen University Hospital, Comprehensive Cancer Center Erlangen-EMN, Friedrich Alexander University of Erlangen-Nuremberg, 91054 Erlangen, Germany
- Pauline Wimberger
- Department of Gynecology and Obstetrics, Carl Gustav Carus Faculty of Medicine and University Hospital, Technical University of Dresden, 01307 Dresden, Germany
- Carsten Hielscher
- g.SUND Gynäkologie-Onkologisches Zentrum, 18435 Stralsund, Germany
- Christoph Mundhenke
- Department of Gynecology and Obstetrics, Klinik Hohe Warte, 95445 Bayreuth, Germany
- Christian Kurbacher
- Department of Gynecology I (Gynecologic Oncology), Gynecologic Center Bonn-Friedensplatz, 53111 Bonn, Germany
- Rachel Wuerstlein
- Department of Gynecology and Obstetrics, Breast Center and CCC Munich, Munich University Hospital, 81377 Munich, Germany
- Michael Untch
- Department of Gynecology and Obstetrics, Helios Clinics Berlin-Buch, 13125 Berlin, Germany
- Friedrich Overkamp
- OncoConsult Overkamp GmbH, 10557 Berlin, Germany
- Jens Huober
- Department of Gynecology and Obstetrics, Ulm University Hospital, 89075 Ulm, Germany
- Wolfgang Janni
- Department of Gynecology and Obstetrics, Ulm University Hospital, 89075 Ulm, Germany
- Florin-Andrei Taran
- Department of Gynecology, Zurich University Hospital, 8091 Zurich, Switzerland
- Michael P. Lux
- Kooperatives Brustzentrum Paderborn, Department of Gynecology and Obstetrics, Frauenklinik St. Louise, Paderborn, St. Josefs-Krankenhaus, Salzkotten, 33098 Paderborn, Germany
- Diethelm Wallwiener
- Department of Obstetrics and Gynecology, University of Tübingen, 72076 Tübingen, Germany
- Sara Y. Brucker
- Department of Obstetrics and Gynecology, University of Tübingen, 72076 Tübingen, Germany
- Andreas Schneeweiss
- National Center for Tumor Diseases, Heidelberg University Hospital, German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany
- Tanja N. Fehm
- Department of Gynecology and Obstetrics, Düsseldorf University Hospital, 40225 Düsseldorf, Germany
- DOI
- https://doi.org/10.3390/cancers12103021
- Journal volume & issue
-
Vol. 12,
no. 10
p. 3021
Abstract
The approval of trastuzumab emtansine (T-DM1) was conducted without pertuzumab as previous therapy. Efficacy data on T-DM1 following pertuzumab treatment are therefore limited. This study explores this issue in a real-world setting. Within the prospective PRAEGNANT (Prospective Academic Translational Research Network for the Optimization of the Oncological Health Care Quality in the Advanced Setting) metastatic breast cancer registry (NCT02338167), patients in all therapy lines receiving any kind of treatment were eligible for inclusion. This report describes patient characteristics and progression-free survival (PFS) in human epidermal growth factor receptor 2 (HER2)-positive patients receiving T-DM1 after pertuzumab treatment. Seventy-six patients were identified, 39 of whom received T-DM1 as second-line therapy, 25 as third-line, and 12 as fourth-line therapy or higher. Pertuzumab was mostly administered as a first-line treatment (n = 61; 80.3%). The median PFS in all patients was 3.5 months (95% CI: 2.8–7.8); in second-line treatment, 7.7 months (95% CI: 2.8–11.0); in third-line, 3.4 months (95% CI: 2.3–not reached (NR)); and in fourth-line therapy or higher, 2.7 months (95% CI: 1.2–NR). T-DM1 was mainly administered second-line after pertuzumab, but also in more heavily pretreated patients. The PFS in higher therapy lines appears to be shorter than in second-line.
Keywords